QL1706

Generic Name: QL1706

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: -

Background: QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Phase 3

Not yet recruiting

Conditions: Colon Cancer

Interventions: Biological: QL1706
Drug: CAPEOX

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 288

Registration Number: NCT06686576

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Platinum-resistant Recurrent Ovarian Cancer

Interventions: Drug: QL1706

First Posted Date: 2024-07-19

Last Posted Date: 2024-07-19

Lead Sponsor: West China Second University Hospital

Target Recruit Count: 39

Registration Number: NCT06509971

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Phase 2

Not yet recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: QLS31905
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Chemotherapy drug
Drug: Gemcitabine
Drug: Capecitabine
Drug: QL1706

First Posted Date: 2024-06-06

Last Posted Date: 2024-06-06

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 360

Registration Number: NCT06446388

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: QL1706
Drug: Nab-paclitaxel
Drug: Gemcitabine
Drug: Bevacizumab

First Posted Date: 2024-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT06313970

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: QL1706
Drug: Bevacizumab
Drug: Sintilimab
Drug: Oxaliplatin injection
Drug: Capecitabine

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 668

Registration Number: NCT05976568

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳
Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Phase 2

Recruiting

Conditions: Colorectal Carcinoma

Interventions: Drug: QL1706
Drug: Bevacizumab
Drug: Oxaliplatin injection
Drug: Capecitabine

First Posted Date: 2023-04-05

Last Posted Date: 2023-05-25

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT05799820

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Tilesizumab
Drug: QL1706

First Posted Date: 2023-01-19

Last Posted Date: 2023-01-19

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 650

Registration Number: NCT05690945

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Advanced Liver Cancer

Interventions: Drug: QL1604
Drug: QL1706
Drug: Bevacizumab

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT05603039

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Carrelizumab
Drug: QL1706
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2022-10-12

Last Posted Date: 2023-11-22

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT05576272

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangzhou, China

A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: QL1706

First Posted Date: 2022-09-28

Last Posted Date: 2022-09-28

Lead Sponsor: Qilu Pharmaceutical Co., Ltd.

Target Recruit Count: 150

Registration Number: NCT05557565

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy